1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Livestock Vaccines Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Livestock Vaccines Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. Key Industry Events
5.4. COVID-19 Pandemic Impact on Industry
6. Global Livestock Vaccines Market Analysis and Forecast, by Vaccine Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2023–2031
6.3.1. Bovine Vaccine
6.3.2. Poultry Vaccine
6.3.3. Porcine Vaccine
6.3.4. Others
6.4. Market Attractiveness Analysis, by Vaccine Type
7. Global Livestock Vaccines Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2023–2031
7.3.1. Live Attenuated Vaccine
7.3.2. Inactivated Vaccine
7.3.3. Recombinant Vaccine
7.3.4. Others
7.4. Market Attractiveness Analysis, by Technology
8. Global Livestock Vaccines Market Analysis and Forecasts, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2023–2031
8.3.1. Oral
8.3.2. Parenteral
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Livestock Vaccines Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2023–2031
9.3.1. Veterinary Hospitals
9.3.2. Veterinary Clinics
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Livestock Vaccines Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2023–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Livestock Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vaccine Type, 2023–2031
11.2.1. Bovine Vaccine
11.2.2. Poultry Vaccine
11.2.3. Poultry Vaccine
11.2.4. Others
11.3. Market Value Forecast, by Technology, 2023–2031
11.3.1. Live Attenuated Vaccine
11.3.2. Inactivated Vaccine
11.3.3. Recombinant Vaccine
11.3.4. Others
11.4. Market Value Forecast, by Route of Administration, 2023–2031
11.4.1. Oral
11.4.2. Parenteral
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2023–2031
11.5.1. Veterinary Hospitals
11.5.2. Veterinary Clinics
11.5.3. Others
11.6. Market Value Forecast, by Country, 2023–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Vaccine Type
11.7.2. By Technology
11.7.3. By Route of Administration
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Livestock Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2023–2031
12.2.1. Bovine Vaccine
12.2.2. Poultry Vaccine
12.2.3. Porcine Vaccine
12.2.4. Others
12.3. Market Value Forecast, by Technology, 2023–2031
12.3.1. Live Attenuated Vaccine
12.3.2. Inactivated Vaccine
12.3.3. Recombinant Vaccine
12.3.4. Others
12.4. Market Value Forecast, by Route of Administration, 2023–2031
12.4.1. Oral
12.4.2. Parenteral
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2023–2031
12.5.1. Veterinary Hospitals
12.5.2. Veterinary Clinics
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Vaccine Type
12.7.2. By Technology
12.7.3. By Route of Administration
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Livestock Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2023–2031
13.2.1. Bovine Vaccine
13.2.2. Poultry Vaccine
13.2.3. Porcine Vaccine
13.2.4. others
13.3. Market Value Forecast, by Technology, 2023–2031
13.3.1. Live Attenuated Vaccine
13.3.2. Inactivated Vaccine
13.3.3. Recombinant Vaccine
13.3.4. Others
13.4. Market Value Forecast, by Route of Administration, 2023–2031
13.4.1. Oral
13.4.2. Parenteral
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2023–2031
13.5.1. Veterinary Hospitals
13.5.2. Veterinary Clinics
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Vaccine Type
13.7.2. By Technology
13.7.3. By Route of Administration
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Livestock Vaccines Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2023–2031
14.2.1. Bovine Vaccine
14.2.2. Poultry Vaccine
14.2.3. Porcine Vaccine
14.2.4. Others Vaccine
14.3. Market Value Forecast, by Technology, 2023–2031
14.3.1. Live Attenuated Vaccine
14.3.2. Inactivated Vaccine
14.3.3. Recombinant Vaccine
14.3.4. Others
14.4. Market Value Forecast, by Route of Administration, 2023–2031
14.4.1. Oral
14.4.2. Parenteral
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2023–2031
14.5.1. Veterinary Hospitals
14.5.2. Veterinary Clinics
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Vaccine Type
14.7.2. By Technology
14.7.3. By Route of Administration
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Livestock Vaccines Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vaccine Type, 2023–2031
15.2.1. Bovine Vaccine
15.2.2. Poultry Vaccine
15.2.3. Porcine Vaccine
15.2.4. Others
15.3. Market Value Forecast, by Technology, 2023–2031
15.3.1. Live Attenuated Vaccine
15.3.2. Inactivated Vaccine
15.3.3. Recombinant Vaccine
15.3.4. Others
15.4. Market Value Forecast, by Route of Administration, 2023–2031
15.4.1. Oral
15.4.2. Parenteral
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2023–2031
15.5.1. Veterinary Hospitals
15.5.2. Veterinary Clinics
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2023–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Vaccine Type
15.7.2. By Technology
15.7.3. By Route of Administration
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Dechra Pharmaceuticals PLC
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Ceva Santé Animale
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Elanco
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Merck & Co., Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Zoetis Services LLC
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Boehringer Ingelheim International GmbH.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Virbac
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Biogénesis Bagó
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Ourofino Saúde Animal
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. VETAL Animal Health Products, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Other prominent Players
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
